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Abstract
Recent studies in the field of autoimmune thyroid diseases have largely focused on the delineation
of B-cell auto-epitopes recognized by the main autoantigens to improve our understanding of how
these molecules are seen by the immune system. Among these autoantigens which are targeted by
autoantibodies during the development of autoimmune thyroid diseases, thyroid peroxidase is a
major player. Indeed, high amounts of anti-thyroid peroxidase autoantibodies are found in the sera
of patients suffering from Graves' disease and Hashimoto's thyroiditis, respectively hyper and
hypothyroidism. Since anti-thyroid peroxidase autoantibodies from patients'sera mainly recognize
a discontinuous immunodominant region on thyroid peroxidase and due to the complexity of the
three dimensional structure of human thyroid peroxidase, numerous investigations have been
necessary to closely localize this immunodominant region. The aim of the present review is to
summarize the current knowledge regarding the localization of the immunodominant region
recognized by human thyroid peroxidase-specific autoantibodies generated during the
development of autoimmune thyroid diseases.
1. Introduction
Autoimmune Thyroid Diseases (AITD) are one of the
most frequent organ-specific autoimmune diseases affect-
ing more than 3% of the total population worldwide. The
clinical spectrum can be divided into two major subtypes,
(i) glandular hyperfunction characterized by Graves' dis-
ease, and (ii) glandular hypofunction as Hashimoto's thy-
roiditis. In both diseases, there is a breakdown in
tolerance and the generation of an immunoglobulin G
response directed against thyrotropin receptor (predomi-
nantly in Graves' disease [1,2]), thyroglobulin, and thy-
roid peroxidase (TPO). Autoantibodies (aAbs) against
TPO, a common denominator of AITD, are present in
90% of Hashimoto's thyroiditis and 75% of Graves' dis-
ease patients' sera [3]. Since anti-TPO aAbs are present at
high concentration in patients' sera [4,5], they are invalu-
able makers of the thyroid autoimmune response and
thus extensively used to diagnose such pathologies. In
vitro and in vivo cytotoxic effector functions have also been
described such as C3 complement activation [6-8] and
antibody-dependent cell cytotoxicity [9-12] leading to the
maintenance and amplification of thyroid cell destruction
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in Hashimoto's disease. Moreover, anti-TPO aAbs are
likely to play a more important role in presenting TPO to
T cells [5,13,14]. To understand the role of anti-TPO aAbs
in the pathogenesis of AITD and to shed new light on how
the TPO molecule is seen by the immune system, the
delineation of anti-TPO B-cell epitopes has been the goal
of several studies during the last decades. These findings
enabled a better localization of the discontinuous immu-
nodominant region (IDR) with the description of several
amino acid residues taking part in this highly complex
structure. All together, these data could be a great interest
to rationally design competitors (such as peptides) which
could be used in combination with other immunothera-
pies such as systemic antibody treatment, antigen-specific
immunization or others generating antigen-specific regu-
latory T cells capable to block at least for a period of time,
an ongoing autoimmune process and may synergize to
delay hypothyroiditis.
2. TPO : structure and function
TPO is a membrane-bound, glycosylated hemoprotein
that plays a key role in thyroid hormone synthesis by cat-
alyzing both the iodination of thyroglobulin and the cou-
pling of some of the iodotyrosyl residues to generate the
thyroid hormones T3 and T4. Human TPO (hTPO) is a
933 amino acid type I integral apical membrane protein
that contains a large extra-cytoplasmic domain orientated
toward the follicular lumen, a short membrane-spanning
region, and a 61 amino acids cytoplasmic tail. The extra-
cellular region consists of 848 amino acids and five poten-
tial glycosylation sites. Alignment studies and structural
homologies have shown that hTPO is formed by three dis-
tinct domains: a myeloperoxidase (MPO)-like, a comple-
ment control protein (CCP)-like, and an epidermal
growth factor (EGF)-like domains, from the N- to the C-
terminal extremities [15] (Figure 1). The high homology
between the MPO and TPO molecules has allowed the
prediction of the secondary structure and domain organi-
zation of TPO [16] which is composed mainly of alpha-
helical structure with relatively little beta-sheet structures.
More recently, the structure of each domain has been par-
tially elucidated by three-dimensional modeling [17,18].
The three-dimensional structure of TPO, however,
remains unknown, even though low resolution crystals
have been obtained [19,20]. TPO is known to exist as
multiple species and migrates on SDS PAGE analysis as a
closely spaced doublet, which derives from endogenous
proteolysis [21,22]. The multiplicity of N-terminal trun-
cated forms of TPO contributing to the diversity of the
polypeptide chain, and the flexibility observed for the
hinge regions leading to an instable form of TPO, have
made difficult to obtain high resolution diffracting crys-
tals for three dimensional structural analysis. Probably,
the only way to solve the three-dimensional structure of
TPO will be to "freeze" the molecule in a stable conforma-
tion by crystallizing a complex TPO/anti-TPO Fab. This
strategy would be also greatly informative to define all res-
idues involved in the interaction. Nevertheless, because of
the difficulty in obtaining diffracting crystals, other strate-
gies, such as competition between anti-TPO aAbs, site-
directed mutagenesis or construction of chimera, have
been used to delineate B-cell autoepitopes on the TPO
molecule [17,23].
3. Anti-TPO autoantibodies and 
immunodominant region
Anti-TPO aAbs are specific serological markers for diag-
nosing AITD. Anti-TPO aAbs are produced by B lym-
phocytes via a T cell-dependent mechanism. Since several
years, it is well known that anti-TPO aAbs recognize con-
formational epitopes that are highly dependent on the
three-dimensional structure of the TPO molecule [2].
These TPO aAbs are known to be restricted to two immu-
nodominant regions (IDR) containing different but adja-
cent surface epitope. In 1989, Ruf and Carayon's group
[24] pioneered in the localization on antigenic domains
on hTPO. Using a panel of monoclonal antibodies
(mAbs) with different affinities and epitopic specificities
for hTPO, they studied the distribution of epitopes on the
surface of the hTPO molecule. These mAbs were found to
interact with four domains (termed A to D) on native
TPO. But, in competitive experiments with sera from
patients suffering from AITD, only the binding of mAbs
interacting with the two major antigenic domains (named
A and B) was highly inhibited by anti-TPO aAbs from
patients' sera, demonstrating that these two regions form
the IDR on the hTPO.
During the last two decades, an explosion in the develop-
ment of combinatorial libraries technologies enable the
production of anti-TPO human mAb fragment from sev-
eral phage display antibody libraries constructed by using
thyroid infiltrating B-cells from Graves' disease or Hashi-
moto's thyroiditis patients. Using a panel of four anti-TPO
antibody fragments (Fabs), named SP1-5, WR1-7, TR1-8
and TR1-9, Chazenbalk and co-workers [25] showed that
these four recombinant human Fabs inhibit more than
90% of anti-TPO aAbs present in patients' sera affected by
AITD. Thus, they have been concluded that these four
Fabs recognize epitopes that delineate the IDR of hTPO.
Interestingly, the IDR was found to be composed by two
overlapping regions (named A and B domains) as previ-
ously described with the mouse mAbs (but the domains
were described with an inverted nomenclature) [25-27].
Our group also contributed to increase the number and
diversity of human monoclonal anti-TPO aAbs using the
phage display technology. Forty-four human anti-TPO
aAbs were selected from one "in cell" library and three
random combinatorial libraries constructed from differ-
ent B-cell subsets extracted from thyroid biopsies fromJournal of Autoimmune Diseases 2005, 2:2 http://www.jautoimdis.com/content/2/1/2
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Ribbon diagram of the structure of human TPO Figure 1
Ribbon diagram of the structure of human TPO. (Reproduced with permission 14). The MPO- (residues 142–733), 
CCP- (residues 739–795) and EGF-like (residues 796–841) domains are indicated with a black arrow. This representation cor-
responds to the juxtaposition of the three-dimensional model of each domain.
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Graves' disease patients [28,29]. These recombinant
human anti-TPO aAbs, mimicking the human repertoire,
strongly displace the binding of anti-TPO aAbs present in
patients' sera (80% inhibition) to hTPO, and predomi-
nantly recognize the IDR.
Competitive experiments between human anti-TPO aAbs
from patients' sera and anti-TPO aAbs (human Fabs or
mouse mAbs), were used to draw contours of the IDR/A
and IDR/B on the TPO molecule. However competition
studies do not allow the precise localization of the IDR as
well as the identification of the amino acid residues
involved in the interaction. Consequently, other
approaches were investigated with the aim of (i) defining
the contribution of each domains (A and B) in the IDR,
(ii) identifying key residues involved in the IDR/A and
IDR/B-specific human anti-TPO aAbs epitopes, and (iii)
understanding the relationship that could exist between
both domains.
4. Contribution of the MPO-like and CCP-like 
domains in the IDR
The MPO-like domain has been clearly found to contrib-
ute in the folding of the IDR (IDR/A and IDR/B). It is
important to note that the A domain defined by the
murine mAbs corresponds to the B domain defined by the
human Fabs and vice versa. Since we have used human
anti-TPO aAb in our experiments as did McLachlan and
Rapoport's group [30], we use here the nomenclature of
the IDR/A and B defined by this group. Banga and Gardas'
groups chose to produce a panel of polyclonal anti-sera by
immunizing rabbits with a series of overlapping or adja-
cent peptide sequences exposed at the surface of TPO
(based upon the TPO model). By using a rabbit antiserum
against the peptide P14 (aa 599–617), they successfully
located the IDR/A epitope on hTPO in the MPO-like
domain. Importantly, this region is included in the
recombinant fragment of hTPO (aa 589–633) which was
previously identified as an autoantigenic determinant
[31].
Amongst the panel of mAbs produced by Ruf and
Carayon's group [24], only mAb 47 binds to both, dena-
tured and native TPO. This mAb recognizes a linear
epitope first located between amino acid residues 713–
721 [32] and later restricted to residues 713–717 [33].
Interestingly, mAb 47 was shown to strongly competes
with IDR/B-specific human anti-TPO aAbs thus defining
for the first time a short immunoreactive IDR/B-specific
region [30,37]. Furthermore, mutations between the posi-
tions 713–717 specifically affected the binding of
patients' sera to hTPO, definitively demonstrating that
this region in MPO-like domain is involved in the IDR/B
epitope. In the past five years, three other regions (210–
225, 353–363, 549–563) [15,33,34], structuring the IDR/
B have been identified in the MPO-like region (Figure 2A).
Finally using a chimeric molecule between TPO and MPO
molecules, the 121 amino-terminal residues of TPO were
excluded from the IDR [35].
On the other hand, the participation of the CCP-like
domain in the IDR was more difficult to demonstrate. In
1998, Estienne et al, [36] located a conformational B-cell
epitope at the C-terminal end of TPO near the membrane
anchorage domain of the molecule (amino acids 742–
848). Since the majority of anti-TPO aAbs from Hashim-
oto patients' sera recognized a recombinant polypeptide
encompassing this region, the authors thought that this
region was part of the IDR. One year later, using reticulo-
cyte lysate cell-free translation approach of TPO, Grennan
et al [37] observed that truncation of TPO downstream of
amino acid residue 771 had little effect on aAb recogni-
tion in all patients' sera tested, suggesting that the IDR rec-
ognized by human aAbs should lie between amino acid
residues 742 and 771. This observation was in agreement
with the early study from Estienne et al, but later, Xiong et
al  [38], using the cell-free translation approach, con-
cluded that the region 742–771 does not contain the IDR.
These contradictory data underline the difficulty of deter-
mining the contribution of the CCP-like domain in the
IDR, specially when the CCP-like domain is expressed and
studied outside the three-dimensional context of the
hTPO (as exemplified with the in vitro translation experi-
ments). To overcome such problems, and with the aim to
localize the discontinuous IDR of the TPO, we have com-
bined two technological advances (i) the selection of
mimotopes by screening phage display peptides libraries
on an IDR/B-specific human recombinant anti-TPO aAb
(T13) mimicking aAbs from patients' sera, and (ii) the
sequence alignment of the selected mimotopes on the pri-
mary sequence of hTPO [33]. We identified four distinct
regions distributed between the MPO- and CCP-like
domains. The sequences 353–363, 377–386, and 713–
720, are located in the MPO-like domain while the last
one, in position 766–775, is located in the CCP-like
domain. More interestingly, mutation of the region 766–
775 abrogated the binding of human anti-TPO aAbs from
Hashimoto's and Graves' disease patients. In the contrary,
the EGF-like domain of the TPO molecule was clearly
excluded from the IDR [39], as well as the contact region
between the two TPO monomers during the dimerisation
of the molecule [35].
All together, these data pointed out (i) the participation of
several regions in the MPO-like domain and at least one
region (766–775) in the CCP-like domain for the folding
of the IDR and (ii) that one major region (599–617)
belongs to the IDR/A and five regions (210–225, 353–
363, 549–563, 713–720, and 766–775) structure the
IDR/B. This emphasizes the discontinuous nature as wellJournal of Autoimmune Diseases 2005, 2:2 http://www.jautoimdis.com/content/2/1/2
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as the complexity of the IDR and provides new insights
into the MPO-like and CCP-like domains positioning. It is
now obvious that the MPO-like and CCP-like domains
have to be closed in the three-dimensional structure of
hTPO to form an immunodominant binding surface rec-
ognized by the majority of anti-TPO aAbs, thus one could
hypothesize that the CCP-like domain may be able to fold
onto the MPO-like domain to enable the binding of a sin-
gle aAb simultaneously to the MPO- and CCP-like
domains (Figure 2B) [33].
5. Amino acid residues structuring the IDR
To improve our knowledge of IDR and to understand how
the TPO is seen by the immune system during the patho-
genesis of AITD, it was also important to determine the
amino acid residues involved in the epitopes recognized
by human anti-TPO aAbs. Among the major regions iden-
tified over time, contributing amino acid residues have
been identified. By expressing recombinant hTPO
mutants with single amino acid replacements, several
groups participated to the characterization of critical
Location of the regions participating in the IDR Figure 2
Location of the regions participating in the IDR. (A) Regions involved in the binding with aAbs are indicated on a three-
dimensional diagram of the human TPO : positions 353–363 in yellow, 377–386 in red, 506–514 in green, 713–720 in blue, 
599–617 in orange in the MPO-like domain, 737–740 in pink, and 766–775 in orange in the CCP-like domain. The flexibility of 
the hinge regions is represented by a white arrow. (B) Ribbon diagram representing the possible folding of the CCP-like 
domain onto the MPO-like domain. An immunodominant binding surface is virtually represented by three dotted lines and the 
distance (in Å) between the regions 377–387 and 713–720 is shown. The model was adjusted by using Swiss-PDB viewer 3.7b2 
freeware available at http://www.expasy.ch/spdbv.Journal of Autoimmune Diseases 2005, 2:2 http://www.jautoimdis.com/content/2/1/2
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amino acid residues. [17,34,40,41]. Although, seven key
residues (R225, Y772, and K713 to D717) involved in the
IDR/B-specific anti-TPO aAbs epitope were identified,
only one amino acid residue (K627) has been clearly
assigned to the IDR/A-specific human anti-TPO aAb
epitope.
6. Respective positioning of IDR/A and IDR/B
The two main discontinuous IDR (known as IDR/A and
IDR/B) have been studied for several years to identify the
TPO amino acid sequences involved in the binding of
human anti-TPO aAbs. Over time, a body of evidence
demonstrated that IDR/A and IDR/B, although different,
overlap in part [25,27]. Thus, in spite of the growing
number of data available for delimiting each domain (A
and B) forming the entire IDR, it was unclear whether
these domains (i) form two separate clusters recognized
by either IDR/A- or IDR/B-specific human anti-TPO aAbs
or (ii) are structurally similar (involving the same surface
area on the TPO molecule). Using all the reference anti-
TPO Abs (recombinant human Fabs, mouse mAbs and
rabbit polyclonal anti-peptides), with the same approach,
the relationship between IDR/A and IDR/B domains has
been investigated [42]. We have demonstrated that
human IDR/A and IDR/B-specific anti-TPO aAbs recog-
nize essentially the same region on the surface of hTPO.
However, IDR/A-specific aAbs use the region 599–617 as
anchor point for their binding to hTPO much more force-
fully (Figure 3).
Such observations emphasize, once again, the high com-
plexity of the IDR on the TPO molecule. It has been now
well demonstrated that the IDR is stretched along the
MPO- and CCP-like domains of hTPO. Consequently,
some regions such as the region 599–617, 713–720, and
772–775 seem to be too far, on the three dimensional
model of hTPO, to compose a single epitope, albeit dis-
continuous. Furthermore, a rapid inspection of the three
dimensional TPO model shows that region 599–617 (the
main anchor point for the IDR/A-specific aAbs) is located
on the opposite side of the MPO-like domain with regard
to the immunodominant binding surface composed of
three auto-reactive TPO peptide sequences (353–363,
713–720 or 766–775) (Figure 2B). Until now, the only
three-dimensional structure of hTPO known is a compu-
ter model and the whole structure of hTPO could be more
compact than the model suggested. Thus, a flexibility in
the hinge region between the MPO-, CCP- and EGF-like
IDR/A and IDR/B-specific anti TPO aAbs mainly recognize the same regions on hTPO: the binding strength makes the  difference Figure 3
IDR/A and IDR/B-specific anti TPO aAbs mainly recognize the same regions on hTPO: the binding strength 
makes the difference. IDR/A- and IDR/B- specific epitopes (left and right panel respectively) are globally composed by the 
same peptidic regions on hTPO. Region 599–617 (in orange) represents the amino acid sequence predominantly recognized by 
IDR/A-specific anti-TPO aAbs (as illustrated by three yellow lines on the left panel). On the hand, IDR/B-specific anti-TPO 
aAbs bind several regions widely spread on the IDR. The immunodominant binding surface (in blue) and region 599–617, com-
posed the IDR/B-specific epitopes as shown by the yellow lines which illustrate the contact points on hTPO. As not shown in 
the figure, the CCP-like domain may contribute to the immunodominant epitopes.
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domains would lead to the formation of a more closely
folded molecule [17,33]. Furthermore, the membrane-
bound TPO, at the surface of thyrocytes as well as CHO
cells, exists as a disulfide-linked dimer [43]. Thus the pres-
ence of TPO dimer could favor a spatial gathering of the
IDRs recognized by IDR/A and IDR/B-specific anti-TPO
aAbs. Since, anti-TPO aAbs epitopes are largely restricted
to one facet of the native molecule [24,25,33] this may
enable the formation of a dimer by the other side, as pre-
viously modeled by homology with the crystal structure of
the MPO molecule [15].
7. Concluding remarks
Numerous efforts have been made to precisely character-
ize the regions, as well as the amino acid residues forming
the IDR of hTPO. This could lead to the rational design of
therapeutic peptides able to modulate or block immune
responses such as antigen presentation. Thus, it would be
of great interest to determine in vivo, by using animals
models for AITD, whether it will be possible to influence
the diseases' course (rapidity, severity, etc...) by using
these peptidic immunomodulators interacting with anti-
gen presentation of B-cells to T-cells.
However, a major question remains: What is the clinical
significance of the anti-TPO aAbs which are present in the
two well characterized AITD (Graves' disease and
Hashimoto's thyroiditis)? Although, there is a general
consensus that one of the most important markers of thy-
roid autoimmunity is the production of such thyroid-spe-
cific aAbs. Their role during the pathogenesis of AITD is
still controversial.
Several lines of evidence show that there is no difference
in the epitope recognized by anti-TPO aAbs produced dur-
ing Graves' disease, Hashimoto's thyroiditis and Euthy-
roiditis [44-46], and it is well-known that epitope
spreading phenomenon does not occur in patients suffer-
ing from these diseases, at least for the B-cell epitopes [5].
Since, the components of the IDR/A and IDR/B of hTPO
are now well characterized, it would be interesting to eval-
uate by longitudinal studies, whether the epitopic pattern
of individual patients is changing (from an IDR/A to IDR/
B pattern for example or vice versa) during the course of
the diseases or after treatment.
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